Biopharma Due for Rebound

The biopharmaceutical industry is showing increased optimism for growth over the next 12 months, according to GlobalData. In the “State of the Biopharmaceutical Industry 2024 (mid-year update)” survey, 73% of healthcare industry professionals expressed optimism, a rise from 60% six months ago and 47% in 2023, though still below the 81% confidence level of 2022. Only 7% expressed some kind of pessimism, showing that there is a strong consensus that things are getting better.

The Senior Director at GlobalData noted that despite geopolitical challenges, a decline in inflation is creating a stable environment for biotech funding, signaling recovery. Reduced supply chain disruptions further suggest a rebound from COVID-19 and geopolitical impacts.

However, geopolitical conflicts and drug pricing pressures remain significant challenges. Geopolitical tensions disrupt international relations and supply chains, while pricing pressures, such as those from the US Inflation Reduction Act, affect profitability and investment. While growth prospects are promising, these factors may influence investment confidence and industry growth.

Read more about the survey here:

Related Articles